Prescient Therapeutics Limited
Prescient Therapeutics Limited
Your view on PTX.AX
Overview
What the company does, where it operates, and who runs it.
About Prescient Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James McDonnell
- Headquarters
- Suite 2, Melbourne, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- James McDonnell
- Headquarters
- Suite 2, Melbourne, VIC, AU
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types.
The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies.
Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations.
Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform.
Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Prescient Therapeutics Limited. Starting points for Prescient Therapeutics Limited: EPS -AUD 0.0067, beta 0.73 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Prescient Therapeutics Limited. Prescient Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Prescient Therapeutics Limited. Trailing twelve-month EPS for Prescient Therapeutics Limited stands at -AUD 0.0067. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This yearYear to Jun 2018 | Next yearYear to Jun 2024 |
|---|---|---|
| Average estimate | AUD 0.01 | −AUD 0.04 |
| Lowest estimate | AUD 0.01 | −AUD 0.04 |
| Highest estimate | AUD 0.01 | −AUD 0.04 |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Revenue estimates
| Total | This yearYear to Jun 2018 | Next yearYear to Jun 2024 |
|---|---|---|
| Average estimate | AUD 12.91M | AUD 2.00M |
| Lowest estimate | AUD 12.91M | AUD 2.00M |
| Highest estimate | AUD 12.91M | AUD 2.00M |
| Number of analysts | 1 | 1 |
| A year ago | — | — |
| Growth vs a year ago | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Prescient Therapeutics Limited. Prescient Therapeutics Limited has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ADO.AXAnteoTech Limited | Basic Materials | Chemicals - Specialty | — | ||
| AGN.AXArgenica Therapeutics Ltd | Healthcare | Biotechnology | — | ||
| ATX.AXAmplia Therapeutics Limited | Healthcare | Biotechnology | — | ||
| CYP.AXCynata Therapeutics Limited | Healthcare | Biotechnology | — | ||
| IIQ.AXINOVIQ Ltd | Healthcare | Medical - Diagnostics & Research | — | ||
| NOX.AXNoxopharm Limited | Healthcare | Biotechnology | — | ||
| NSB.AXNeuroScientific Biopharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PALIPalisade Bio, Inc. | Healthcare | NASDAQ | $168.9M | ||
| PANCPanacos Pharmaceuticals, Inc. | Healthcare | OTC | $5,367 | ||
| PAR.AXParadigm Biopharmaceuticals Limited | Healthcare | ASX | — | ||
| PARDPoniard Pharmaceuticals, Inc. | Healthcare | OTC | $150 | ||
| PASGPassage Bio, Inc. | Healthcare | NASDAQ | $12.9M | ||
| PBIGFParadigm Biopharmaceuticals Limited | Healthcare | OTC | $87.9M | ||
| PBLAPanbela Therapeutics, Inc. | Healthcare | OTC | $53,889 | ||
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.5B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $47,738 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $869 | ||
| PBYIPuma Biotechnology, Inc. | Healthcare | NASDAQ | $373.3M | ||
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.8M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Prescient Therapeutics Limited.